FINWIRES · TerminalLIVE
FINWIRES

SSY Group Gets Bulk Drug Approval for Parkinson's Disease Treatment in China

By

SSY Group (HKG:2005) obtained registration approval for Safinamide Mesylate to become a bulk drug for the preparations on the market from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.

The drug is mainly used for the treatment of Parkinson's disease in combination with other Parkinson's drugs such as levodopa, the filing said.

Related Articles

Asia

Wasion Unit Secures 1.6 Billion Yuan Overseas Orders

Wasion's (HKG:3393) subsidiary, Wayon Energy, secured new overseas business contracts worth more than 1.6 billion yuan from the start of this year through Tuesday, according to a same-day Hong Kong bourse filing.The contracts mainly cover data center infrastructure and related solutions, as well as overseas power distribution products, including reclosers.

$HKG:3393
Asia

Bapcor Turnaround Initiatives Gaining Traction, Weaker Trading Conditions Limiting Near-Term Earnings Flow-through, Jefferies Says

Bapcor's (ASX:BAP) turnaround initiatives are gaining traction operationally, but weaker trading conditions are limiting near-term earnings flow-through, Jefferies said in a Monday note.Bapcor lowered its fiscal 2026 guidance for underlying earnings before interest, taxes, depreciation and amortization (EBITDA) to between AU$144 million and AU$150 million from the previous guidance of AU$150 million to AU$160 million.The downgrade to its underlying EBITDA guidance reflects a business mid-turnaround being impacted the fuel shock caused by the conflict in the Middle East in an already depressed market, with cost inflation and weaker demand driving a fiscal 2026 downgrade despite improving execution.The investment firm upgraded its recommendation to buy from hold and lowered the price target to AU$0.65 from AU$1.05.

$ASX:BAP
Asia

Pine Labs Swings to Profit in Fiscal Q4

Pine Labs (NSE:PINELABS, BOM:544606) swung to a profit in the fiscal fourth quarter ended March 31, with a consolidated profit of 593.6 million Indian rupees from a loss of 289.1 million rupees a year ago.Earnings per share came in at 0.51 rupees compared with a loss per share of 0.28 rupees a year earlier, the digital payments company said in a filing to the Indian stock exchanges on Monday.Revenue from operations in fiscal Q4 rose to 7.01 billion rupees from 5.99 billion rupees a year ago.

$BOM:544606$NSE:PINELABS